Apoptosis gene polymorphisms and risk of prostate cancer: A hospital-based study of German patients treated with brachytherapy

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 1, 2013, Pages 74-81

  Meyer, Andreas ^a   Coinac, Irina ^a   Bogdanova, Natalia ^a   Dubrowinskaja, Natalia ^a   Turmanov, Nurzhan ^a   Haubold, Sabine ^a   Schürmann, Peter ^a   Imkamp, Florian ^a   von Klot, Christoph ^a   Merseburger, Axel S ^a   Machtens, Stefan ^a,b   Bremer, Michael ^a   Hillemanns, Peter ^a   Kuczyk, Markus A ^a   Karstens, Johann H ^a   Serth, Jürgen ^a   Dörk, Thilo ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Marien Krankenhaus Bergisch Gladbach   (Germany)

Author keywords

Apoptosis; Genetic risk; Genetic susceptibility; Programmed cell death; Prostate cancer; Single nucleotide polymorphism

Indexed keywords

ATM PROTEIN; BIOLOGICAL MARKER; CASPASE 10; CASPASE 8; LGALS3 PROTEIN; PROTEIN BCL 2; PROTEIN BID; PROTEIN MDM2; PROTEIN P53; RASSF1 PROTEIN; TP53AIP1 PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; APOPTOSIS; ARTICLE; BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CONTROLLED STUDY; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; TREND STUDY;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BRACHYTHERAPY; CASE-CONTROL STUDIES; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GERMANY; HOSPITALS, UNIVERSITY; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84873994271     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2010.09.011     Document Type: Article

References (50)

1. What Are the Key Statistics About Prostate Cancer? American Cancer Society, Accessed June 30, 2010. http://www.cancer.org/Cancer/ProstateCancer/DetailedGuide/prostate-cancer-key-statistics.
2. Schaid D.J. The complex genetic epidemiology of prostate cancer. Hum Mol Genet 2004, 13(Suppl 1):103-121.
3. Cybulski C. Selected aspects of inherited susceptibility to prostate cancer and tumours of different site of origin. Hereditary Cancer Clin Pract 2007, 5:164-179.
4. Witte J.S. Prostate cancer genomics: Towards a new understanding. Nat Rev Genet 2009, 10:77-82.
5. Veltri R.W., Makarov D.V. Nucleic-acid based marker approaches to urologic cancers. Urol Oncol 2006, 24:510-527.
6. Dong X., Wang L., Taniguchi K., et al. Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet 2003, 72:270-280.
7. Seppälä E.H., Ikonen T., Mononen N., et al. CHEK2 variants associate with hereditary prostate cancer. Br J Cancer 2003, 89:1966-1970.
8. Cybulski C., Górski B., Debniak T., et al. NBS1 is a prostate cancer susceptibility gene. Cancer Res 2004, 64:1215-1219.
9. Wang X., Wang F., Taniguchi K., et al. Truncating variants in p53AIP1 disrupting DNA damage-induced apoptosis are associated with prostate cancer risk. Cancer Res 2006, 66:10302-10307.
10. Ahmadiyeh N., Pomerantz M.M., Grisanzio C., et al. 8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC. Proc Natl Acad Sci U S A 2010, 107:9742-9746.
11. Sotelo J., Esposito D., Duhagon M.A., et al. Long-range enhancers on 8q24 regulate c-Myc. Proc Natl Acad Sci U S A 2010, 107:3001-3005.
12. Diaz J.I., Pow-Sang J.M., Mora L.B., et al. Cytometric analysis of Fas and Bcl-2 expression in normal prostatic epithelium and prostate cancer. Urol Oncol 2000, 5:149-154.
13. Krajewska M., Zapata J.M., Meinhold-Heerlein I., et al. Expression of Bcl-2 family member Bid in normal and malignant tissues. Neoplasia 2002, 4:129-140.
14. Kuzmin I., Gillespie J.W., Protopopov A., et al. The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells. Cancer Res 2002, 62:3498-3502.
15. Merseburger A.S., Kramer M.W., Hennenlotter J., et al. Involvement of decreased Galectin-3 expression in the pathogenesis and progression of prostate cancer. Prostate 2008, 68:72-77.
16. Hirata H., Hinoda Y., Kikuno N., et al. Bcl2-938C/A polymorphism carries increased risk of biochemical recurrence after radical prostatectomy. J Urol 2009, 181:1907-1912.
17. Wang Y., Nangia-Makker P., Tait L., et al. Regulation of prostate cancer progression by galectin-3. Am J Pathol 2009, 174:1515-1523.
18. Danial N.N., Korsmeyer S.J. Cell death: Critical control points. Cell 2004, 116:205-219.
19. Schulze-Bergkamen H., Krammer P.H. Apoptosis in cancer-implications for therapy. Semin Oncol 2004, 31:90-119.
20. Vousden K.H., Lu X. Live or let die: The cell's response to p53. Nat Rev Cancer 2002, 2:594-604.
21. Zhivotovsky B., Kroemer G. Apoptosis and genomic instability. Nat Rev Mol Cell Biol 2004, 5:752-762.
22. Meek D.W. Tumor suppression by p53: A role for the DNA damage response?. Nat Rev Cancer 2009, 9:714-723.
23. Zinkel S.S. Investigation of the pro-apoptotic BCL-2 family member bid on the crossroad of the DNA damage response and apoptosis. Methods Enzymol 2008, 442:231-250.
24. Cory S., Adams J.M. The Bcl2 family: Regulators of the cellular life or death switch. Nat Rev Cancer 2002, 2:647-656.
25. Oda K., Arakawa H., Tanaka T., et al. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by ser-46-phosphorylated p53. Cell 2000, 102:849-862.
26. Esposito F., Tornincasa M., Chieffi P., et al. High-mobility group A1 proteins regulate p53-mediated transcription of Bcl-2 gene. Cancer Res 2010, 70:5379-5388.
27. Califice S., Castronovo V., Bracke M., et al. Dual activities of galectin-3 in human prostate cancer: Tumor suppression of nuclear galectin-3 vs. tumor promotion of cytoplasmic galectin-3. Oncogene 2004, 23:7527-7536.
28. Nakahara S., Oka N., Raz A. On the role of galectin-3 in cancer apoptosis. Apoptosis 2005, 10:267-275.
29. Donninger H., Vos M.D., Clark G.J. The RASSF1A tumor suppressor. J Cell Sci 2007, 120:3163-3172.
30. Chen M., Wang J. Initiator caspases in apoptosis signaling pathways. Apoptosis 2002, 7:313-319.
31. Adams J.M. Ways of dying: Multiple pathways to apoptosis. Genes Dev 2003, 17:2481-2495.
32. Lavrik I.N., Golks A., Krammer P.H. Caspases: Pharmacological manipulation of cell death. J Clin Invest 2005, 115:2665-2672.
33. Meyer A., Wilhelm B., Dörk T., et al. ATM missense variant P1054R predisposes to prostate cancer. Radiother Oncol 2007, 83:283-288.
34. Meyer A., Schürmann P., Ghahremani M., et al. Association of chromosomal locus 8q24 and risk of prostate cancer: A hospital-based study of German patients treated with brachytherapy. Urol Oncol 2009, 27:373-376.
35. Meyer A., Dörk T., Bogdanova N., et al. TGFB1 gene polymorphism Leu10Pro (c. 29T > C), prostate cancer incidence and quality of life in patients treated with brachytherapy. World J Urol 2009, 27:371-377.
36. Kote-Jarai Z., Easton D.F., Stanford J.L., et al. Multiple novel prostate cancer predisposition loci confirmed by an international study: The PRACTICAL Consortium. Cancer Epidemiol Biomarkers Prev 2009, 17:2052-2061.
37. Eeles R.A., Kote-Jarai Z., Al Olama A.A., et al. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet 2009, 41:1116-1121.
38. Cox A., Dunning A.M., Garcia-Closas M., et al. A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet 2007, 39:352-358.
39. Frank B., Hemminki K., Wappenschmidt B., et al. Association of the CASP10 V410I variant with reduced familial breast cancer risk and interaction with the CASP8 D302H variant. Carcinogenesis 2006, 27:606-609.
40. Rupnow B.A., Knox S.J. The role of radiation-induced apoptosis as a determinant of tumor responses to radiation therapy. Apoptosis 1999, 4:115-143.
41. Shiloh Y. ATM and related protein kinases: Safeguarding genome integrity. Nat Rev Cancer 2003, 3:155-168.
42. Angèle S., Falconer A., Edwards S.M., et al. ATM polymorphisms as risk factors for prostate cancer development. Br J Cancer 2004, 91:783-787.
43. Stredrick D.L., Garcia-Closas M., Pineda M.A., et al. The ATM missense mutation p.Ser49Cys (c. 146C > G) and the risk of breast cancer. Hum Mutat 2006, 27:538-544.
44. Dombernowsky S.L., Weischer M., Allin K.H., et al. Risk of cancer by ATM missense mutations in the general population. J Clin Oncol 2008, 26:3057-3062.
45. Gaudet M.M., Milne R.L., Cox A., et al. Five polymorphisms and breast cancer risk: Results from the Breast Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev 2009, 18:1610-1616.
46. Ahmed H., Banerjee P.P., Vasta G.R. Differential expression of galectins in normal, benign and malignant prostate epithelial cells: Silencing of galectin-3 expression in prostate cancer by its promoter methylation. Biochem Biophys Res Commun 2007, 358:241-246.
47. Nangia-Makker P., Raz T., Tait L., et al. Galectin-3 cleavage: A novel surrogate marker for matrix metalloproteinase activity in growing breast cancers. Cancer Res 2007, 67:11760-11768.
48. Balan V., Nangia-Makker P., Schwartz A.G., et al. Racial disparity in breast cancer and functional germ line mutation in galectin-3 (rs4644): A pilot study. Cancer Res 2008, 68:10045-10050.
49. Mandal R.K., Mittal R.D. Are cell cycle and apoptosis genes associated with prostate cancer risk in North Indian population?. Urol Oncol 2010; Sep 3, [Epub ahead of print].
50. Bond G.L., Levine A.J. A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans. Oncogene 2007, 26:1317-1323.